Tracking IUD Bleeding Experiences: An Evaluation of Bleeding Profiles in New Intrauterine Device Users

NCT ID: NCT02311478

Last Updated: 2025-04-16

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 79 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-12-31
• Study Completion Date: 2017-02-28

Brief Summary

This study aims to use validated tools as well as new technology to examine changes in bleeding patterns among women who are initiating the copper T380A IUD.

Detailed Description

New users of the intrauterine device (IUD) are most likely to discontinue use within the first six months after insertion. The most common reason for discontinuation of the copper IUD is symptoms related to bleeding. Research looking at disturbances in bleeding patterns among new IUD users is sparse and dated. Perceived changes in vaginal bleeding may impact method satisfaction, acceptability, and continuation. There is a need for updated research evaluating changes in bleeding patterns in order for providers to better counsel patients on what to expect during the months after initiation of an IUD.

A variety of methods to evaluate bleeding profiles are available. The World Health Organization (WHO) published recommendations for methods of collection and analysis of bleeding patterns. The WHO method includes data collection on bleeding days (days when blood loss requires the use of a menstrual pad or tampon) and spotting days (when no protection was needed) using 90-day referent periods. A second tool, the pictorial blood loss assessment chart (PBAC) has been shown to be an inexpensive and objective method of assessing blood loss. The PBAC takes into consideration how heavy blood flow is as well as the number of sanitary napkins and tampons used. Additionally, new technologies (including mobile period tracking applications) have made retrospective collection of bleeding data more feasible and prospective data collection more accurate.

This study aims to incorporate these validated tools as well as new technology to examine changes in bleeding patterns among women who are initiating the copper T380A IUD.

Conditions

Intrauterine Devices, Copper; Metrorrhagia; Menstruation; Menstrual Cycle

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: SUPPORTIVE_CARE
• Blinding Strategy: NONE

Study Groups

T380A Copper IUD

All participants will receive a T380A copper intrauterine device when enrolled. They can continue using the device for as long as they wish. The study will be completed when 6 months of prospective bleeding data has been collected.

Group Type: EXPERIMENTAL

T380A Intrauterine Copper Contraceptive

Intervention Type: DEVICE

The T380A is intrauterine device (IUD) that used to prevent pregnancy. It is a soft, flexible T-shaped device made primarily of plastic and copper that is inserted into the uterus.

Interventions

T380A Intrauterine Copper Contraceptive

The T380A is intrauterine device (IUD) that used to prevent pregnancy. It is a soft, flexible T-shaped device made primarily of plastic and copper that is inserted into the uterus.

Intervention Type: DEVICE

Other Intervention Names

Paragard

Eligibility Criteria

Inclusion Criteria

• Healthy women ages 18-40 years with regular, normal menses (lasting between 3-7 days) and who are initiating an IUD
• Women who can provide bleeding information for 3 cycles off of any hormonal contraception (or non-hormonal IUD) and are willing to track bleeding for 180 days
• Women who are between 6 and 12 months postpartum (if they have had normal menses the last 3 cycles)

Exclusion Criteria

• Use of any hormonal contraceptive method in the previous 3 months
• Irregular duration of menstrual cycles in the last 3 cycles (<21 or >35 days)
• Recent history of menstrual bleeding lasting less than 3 days or greater than 7 days based on self report of the last 3 cycles
• Contraindication to use of the ParaGard® T380A IUD
• Mucopurulent cervicitis at the time of IUD insertion
• Unable to speak, read, and write in English
• Currently pregnant
• Plans for or desire for pregnancy in the next 6 months
• Currently breastfeeding
• Women who are <6 months postpartum
• Participation in any clinical investigation utilizing an investigational drug or medical device or requiring invasive gynecologic procedures within the 30 days prior to enrollment
• Wilson's disease
• Known coagulopathy or bleeding disorder

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 40 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

University of Utah

OTHER

Sponsor Role: lead

Responsible Party

David Turok

MD

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

David Turok, MD

Role: PRINCIPAL_INVESTIGATOR

Unviersity of Utah

Locations

University of Utah Health Sciences Center

Salt Lake City, Utah, United States

Countries

United States

Other Identifiers

75363

Identifier Type: -

Identifier Source: org_study_id